

**Synthesis of new generation triazolyl and isoxazolyl containing 6-nitro-2,3-dihydroimidazooxazoles as anti-TB agents: *In vitro*, Structure-activity relationship, pharmacokinetics and *in vivo* evaluation**

Gurunadham Munagala,<sup>1,2,†</sup> Kushalava Reddy Yempalla,<sup>1,2,†</sup> Samsher Singh,<sup>2,3,†</sup> Sumit Sharma,<sup>1,2</sup> Nitin Pal Kalia,<sup>3</sup> Vikrant Singh Rajput,<sup>2,3</sup> Sunil Kumar,<sup>2,3</sup> Sanghapal D. Sawant,<sup>1,2</sup> Inshad Ali Khan,<sup>2,3,\*</sup> Ram A. Vishwakarma<sup>1,2,\*</sup> and Parvinder Pal Singh,<sup>1,2,\*</sup>

<sup>1</sup>Medicinal Chemistry Division,

<sup>2</sup>Academy of Scientific and Innovative Research,

<sup>3</sup>Clinical Microbiology,

CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180 001, India

Tel.: +91-191-2569111, Fax: +91-191-2569333,


E-mail: [ppsingh@iiim.ac.in](mailto:ppsingh@iiim.ac.in), [ram@iiim.ac.in](mailto:ram@iiim.ac.in), [iakhan@iiim.ac.in](mailto:iakhan@iiim.ac.in)

## Table of Contents

S.No	Contents	Page Nos
1.	Synthesis and experimental procedures & experimental data of key intermediate <b>3</b>	<b>3-5</b>
2.	Experimental procedures & Experimental data of triazolyl intermediate compounds <b>4 &amp; 5</b>	<b>6-10</b>
3.	Experimental procedures & Experimental data of isoxazolyl intermediate compounds <b>6 &amp; 7</b>	<b>10-14</b>
4.	Spectras ( <sup>1</sup> H NMR, <sup>13</sup> C NMR, DEPT and HRMS) of triazolyl and isoxazolyl based NHIO compounds <b>1 &amp; 2</b>	<b>15-116</b>

## Synthesis of key intermediate 3:

**Scheme S1:**



**Reagents and conditions:** a)  $\text{HNO}_3$ ,  $\text{ACOH}$ ,  $\text{AC}_2\text{O}$ ,  $5^\circ\text{C}$ , 2 h, and then at rt, 12 h; b) chloro benzene,  $120\text{-}125^\circ\text{C}$ , 50 h; c) con  $\text{HCl}$ ,  $90\text{-}95^\circ\text{C}$ , 12 h; d)  $\text{Et}_3\text{N}$ ,  $\text{AcOEt}$ ,  $60\text{-}65^\circ\text{C}$ , 6 h; e)  $\text{K}_2\text{CO}_3$ ,  $\text{MeOH}$ , rt, 2 h; f)  $\text{MsCl}$ , pyridine,  $<15^\circ\text{C}$ , 2 h; g)  $\text{DBU}$ ,  $\text{AcOEt}$ , rt, 2 h.

### 1,4-Dinitroimidazole **S2**:

To a suspension of 4-nitroimidazole (4.0 g, 35.37 mmol) in glacial acetic acid (10 ml) cooled to  $0\text{-}5^\circ\text{C}$  was added fuming nitric acid ( $d=1.52$ ; 5.25 ml) drop wise with stirring, keeping the temperature at or below  $5^\circ\text{C}$  over a period of 30 min. The mixture was cooled to  $0^\circ\text{C}$ , acetic anhydride (19.5 ml) added drop wise, and stirred at  $0^\circ\text{C}$  for 2 h and at room temperature over night. The solid gradually went into the solution, which was extracted with  $\text{CH}_2\text{Cl}_2$  twice and combining the organic layers wash with saturated  $\text{NaHCO}_3$  solution twice and combining organic layers wash with brine solution and dried over anhydrous  $\text{NaSO}_4$  and filtered. The filtrate was concentrated under reduced pressure to give compound **S2** (3.85 g, 69%) as a light yellow solid. TLC (DCM:MeOH 9.5:0.5):  $R_f = 0.20$ ;  $^1\text{H NMR}$  (400 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  9.40 (s, 1H), 8.98 (s, 1H); LC-MS (ESI+):  $m/z$  158.01.

### 2, 4-Dinitroimidazole **S3**:

A mixture of **S2** (3.85 g, 24.3 mmol) in chlorobenzene (40 ml) was heated with stirring at 120 – 125 °C for 50 h on an oil bath, cooled, the solid was filtered and washed with cold chlorobenzene and hexane to yield **S3** ( 3.5 g, 90%) as a light yellow solid. TLC (DCM:MeOH 9.5:0.5):  $R_f$  = 0.30;  $^1\text{H}$  NMR (200 MHz, DMSO- $d_6$ ):  $\delta$  8.48 (s, 1H); LC-MS (ESI+):  $m/z$  158.01.

**2-Chloro-4-nitroimidazole S4:**

2, 4-Dinitroimidazole **S3** (3.5 g, 22.15 mmol) was added to 20 ml of 35 mass% of HCl. The reaction mixture was stirred for 7 hours at 95 °C. After completion of the reaction, 30 ml of water was added and the reaction mixture was cooled to 0 °C for crystallisation. The crystals were filtered and dried to obtain 2-chloro-4-nitroimidazole **S4** (3 g, 92%) as a white solid. TLC (DCM:MeOH 9.5:0.5):  $R_f$  = 0.30;  $^1\text{H}$  NMR (200 MHz, DMSO- $d_6$ ):  $\delta$  8.44 (s, 1H); LC-MS (ESI+):  $m/z$  146.98.

**(R)-2-Chloro-1-[2-hydroxy-2-methyl-3-(4-nitrobenzoyloxy)]-propyl-4-nitroimidazole S6:**

A solution of 2-chloro-4-nitro-1*H*-imidazole **S4** (12 g, 81.36 mmol), (*R*)-form epoxide **S5** (21.24 g, 89.48 mmol), and triethylamine (2.28 mL, 16.28 mmol) in ethyl acetate (40 ml) was heated at 60–65 °C for 6 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give **S6** (27.28 g, 87%) as colourless needles. TLC (EtOAc:hexane 4:6):  $R_f$  = 0.20;  $^1\text{H}$  NMR (200 MHz, DMSO- $d_6$ )  $\delta$  8.42 – 8.30 (m, 3H), 8.25 (d,  $J$  = 8.86 Hz, 2H), 5.61 (s, 1H), 4.32 – 4.12 (m, 4H), 1.25 (s, 3H); LC-MS (ESI+):  $m/z$  384.05.

**(R)-2-Chloro-1-(2,3-dihydroxy-2-methyl)propyl-4-nitroimidazole S7:**

To a solution of **S6** (13.6 g, 35.34 mmol) in methanol (136 mL) was added potassium carbonate (244 mg, 1.76 mmol). After the solution was stirred at room temperature for 2 h, 6 M hydrochloric acid (0.6 mL) and anhydrous sodium sulphate (3 g) were added at 0 °C, and the resulting mixture was stirred for 1 h. The insoluble materials were filtered off through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give **S7** (8.18 g, 97%) as colorless needles. TLC (CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 9.5:0.5): R<sub>f</sub> = 0.20; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 8.28 (s, 1H), 5.07 (t, *J* = 5.6 Hz, 1H), 4.95 (s, 1H), 4.03 (s, 2H), 3.24 (d, *J* = 5.2 Hz, 2H), 1.01 (s, 3H); LC-MS (ESI+): *m/z* 235.04.

**(R)-2-Chloro-1-(2-methyl-2,3-epoxypropyl)-4-nitroimidazole 3:**

To a solution of **S7** (10 g, 42.44 mmol) in pyridine (20 ml) was added methanesulfonyl chloride (7.29 g, 63.66 mmol) at below 15 °C dropwise over 30 min. After the solution was stirred for 2 h, 6 M hydrochloric acid (63 ml) was added to the reaction mixture at below 30 °C. The resulting mixture was extracted with ethyl acetate twice, and the combined organic layer was washed with brine, dried over Sodium sulphate, and filtered. The filtrate was concentrated under reduced pressure to afford crude compound **S8**. To a solution of this crude **S8** in ethyl acetate (100 ml) was added 1,8-diazabicyclo[5.4.0]-7-undecene (7.10 g, 46.68 mmol), and the mixture was stirred at room temperature for 2 h. The reaction mixture was washed with brine, dried over sodium sulphate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give the (*R*)-form epoxide **3** (6.93 g, 75%) as colorless needles. TLC (EtOAc:hexane 4:6): R<sub>f</sub> = 0.30; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 7.88 (s, 1H), 4.39 (d, *J* = 14.87 Hz, 1H), 4.00 (d, *J* = 14.88 Hz, 1H), 2.78 (d, *J* = 3.97 Hz, 1H), 2.63 (d, *J* = 3.92 Hz, 1H), 1.38 (s, 3H); LC-MS (ESI+): *m/z* 217.03.

### **General procedure for the preparation of *O*-Propargylated compounds **10**:**

To a solution of substituted phenols **9** (10 mmol) in ACN (20 mL) was added  $\text{K}_2\text{CO}_3$  (20 mmol) and stirred for 5 minutes. Propargyl bromide **8** (15 mmol) was added slowly to the reaction mixture at room temperature so that the temperature of the reaction should not be increased to above 30 °C. The mixture was stirred at room temperature for 12 h. Then the solvent was removed under reduced pressure and add water into the reaction mixture, extracted with EtOAc twice. The combined organic layers were washed with brine and dried over  $\text{Na}_2\text{SO}_4$ , and concentrated under *vaccum* to afford compounds **10** in 90-95% as light yellow liquid. The residual crude product was used directly in the next reaction without purification.

### **General procedure for the preparation of azidophenols **12**:**

Amino phenols **11** (3.273 g, 30 mmol) was dissolved with 6 N HCl (30 mL) in an ice bath at 0-5 °C.  $\text{NaNO}_2$  solution (3.105 g, 45 mmol in 75 ml of  $\text{H}_2\text{O}$ ) was added drop wise. The reaction mixture was stirred for 30 min at 0-5 °C. Next, a solution of sodium azide (7.8 g, 120 mmol in 120 ml of  $\text{H}_2\text{O}$ ) was added drop wise. After addition, the system was stirred for another hour. Next, the mixture was extracted with ethyl acetate and the combined organic extracts were washed with  $\text{H}_2\text{O}$ , dried over anhydrous  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated in *vaccum* to give **12** as yellow liquids. The residual crude product was used directly without purification.

### **General procedure for the preparation of triazolyl intermediate compounds **4a-m**:**

To a mixture of azido phenol **12** (10 mmol) and substituted phenoxyethylacetylenes **10a-i** (12 mmol) in 1:1  $^t\text{BuOH}$  and water (10 mL) add  $\text{CuSO}_4$  pentahydrate (1 mmol) and sodium ascorbate (2 mmol), The reaction mixture was stirred for 10 to 12 h at room temperature after completion of the reaction add 20 ml water and subsequently extracted with ethyl acetate twice. The combined organic extracts were washed with brine and dried over

anhydrous Na<sub>2</sub>SO<sub>4</sub> filtered, and concentrated in *vaccum*. The residual crude product was purified via silica gel column chromatography using a gradient mixture of hexane-ethyl acetate to obtain the pure triazole intermediate compounds **4a-m** in 85-90% yields.

**4-{4-[(p-Tolyl)oxy]methyl}-1*H*-1,2,3-triazol-1-yl}phenol (**4a**): TLC (EtOAc:Hexane 2:8): R<sub>f</sub> = 0.25; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) δ 8.11 (s, 1H), 7.68 (d, *J* = 8.8 Hz, 2H), 7.15 (d, *J* = 8.4 Hz, 2H), 6.98 (d, *J* = 8.9 Hz, 2H), 6.92 (d, *J* = 8.4 Hz, 2H), 5.26 (s, 2H); LC-MS (ESI+): m/z 281.12.**

**4-{4-[(4-Ethylphenoxy)methyl]-1*H*-1,2,3-triazol-1-yl}phenol (**4b**):** TLC (EtOAc:Hexane 2:8): R<sub>f</sub> = 0.28; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) δ 8.34 (s, 1H), 7.52 (d, *J* = 8.9 Hz, 2H), 7.03 (d, *J* = 8.6 Hz, 2H), 6.87 – 6.83 (m, 4H), 5.09 (s, 2H), 2.48 (q, *J* = 7.5 Hz, 2H), 1.11 (t, *J* = 7.6 Hz, 3H); LC-MS (ESI+): m/z 295.15.

**4-{4-[(4-*iso*-Propylphenoxy)methyl]-1*H*-1,2,3-triazol-1-yl}phenol (**4c**):** TLC (EtOAc: Hexane 2:8): R<sub>f</sub> = 0.30; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) δ 8.35 (s, 1H), 7.53 (d, *J* = 8.9 Hz, 2H), 7.04 (d, *J* = 8.6 Hz, 2H), 6.86 (d, *J* = 8.6 Hz, 2H), 6.84 (d, *J* = 8.89 Hz, 2H), 5.09 (s, 2H), 2.82 – 2.68 (m, 2H), 1.14 (d, *J* = 6.93 Hz, 6H); LC-MS (ESI+): m/z 309.15.

**4-{4-[(4-(*sec*-Butylphenoxy)methyl]-1*H*-1,2,3-triazol-1-yl}phenol (**4d**):** TLC (EtOAc: Hexane 2:8): R<sub>f</sub> = 0.30; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) δ 8.44 (s, 1H), 7.62 (d, *J* = 7.9 Hz, 2H), 7.23 (d, *J* = 7.89 Hz, 2H), 6.97 – 6.93 (m, 4H), 5.19 (s, 2H), 2.59 – 2.50 (m, 1H), 1.57 – 1.51 (m, 2H), 1.18 (d, *J* = 6.87 Hz, 2H), 0.81 (t, *J* = 7.5 Hz, 3H); LC-MS (ESI+): m/z 323.16.

**4-{4-[(4-Fluorophenoxy)methyl]-1*H*-1,2,3-triazol-1-yl}phenol (**4e**):** TLC (EtOAc:Hexane 2:8): R<sub>f</sub> = 0.25; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) δ 8.46 (s, 1H), 7.62 (d, *J* = 8.7 Hz, 2H), 7.04 – 6.94 (m, 6H), 5.19 (s, 2H); LC-MS (ESI+): m/z 285.08.

**4-{4-[(4-Trifluoromethylphenoxy)methyl]-1*H*-1,2,3-triazol-1-yl}phenol (**4f**):** TLC (EtOAc:Hexane 2:8): R<sub>f</sub> = 0.32; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.40 (s, 1H), 7.80 (s, 1H),

7.52 (dd,  $J = 8.7, 6.4$  Hz, 4H), 7.11 (d,  $J = 8.6$  Hz, 2H), 6.85 (d,  $J = 8.9$  Hz, 2H), 5.21 (s, 2H);

LC-MS (ESI+): m/z 335.09.

**4-[4-[(4-Trifluoromethoxyphenoxy)methyl]-1*H*-1,2,3-triazol-1-yl]phenol (4g):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.35$ ;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD) δ 8.38 (s, 1H), 7.52 (d,  $J = 9.0$  Hz, 2H), 7.12 (d,  $J = 9.2$  Hz, 2H), 7.02 (d,  $J = 9.2$  Hz, 2H), 6.85 (d,  $J = 9.0$  Hz, 2H), 5.15 (s, 2H); LC-MS (ESI+): m/z 351.08.

**4-[4-[(2-Fluorophenoxy)methyl]-1*H*-1,2,3-triazol-1-yl]phenol (4h):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (500 MHz, CD<sub>3</sub>OD) δ 8.38 (s, 1H), 7.81 (s, 1H), 7.53 (d,  $J = 8.7$  Hz, 2H), 7.16 (t,  $J = 8.4$  Hz, 1H), 7.01 (dd,  $J = 12.4, 5.9$  Hz, 2H), 6.85 (d,  $J = 9.8$  Hz, 2H), 5.19 (s, 2H); LC-MS (ESI+): m/z 285.09.

**4-[4-[(3-Chlorophenoxy)methyl]-1*H*-1,2,3-triazol-1-yl]phenol (4i):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (500 MHz, CD<sub>3</sub>OD) δ 8.38 (s, 1H), 7.53 (d,  $J = 8.9$  Hz, 2H), 7.18 (t,  $J = 8.2$  Hz, 1H), 6.99 (t,  $J = 2.2$  Hz, 1H), 6.91 – 6.86 (m, 2H), 6.85 (d,  $J = 8.9$  Hz, 2H), 5.13 (s, 2H); LC-MS (ESI+): m/z 301.06.

**3-[4-[(4-Trifluoromethoxyphenoxy)methyl]-1*H*-1,2,3-triazol-1-yl]phenol (4j):** TLC (EtOAc: Hexane 2:8):  $R_f = 0.35$ ;  $^1\text{H}$  NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 8.91 (s, 1H), 7.38 (t,  $J = 8.3$  Hz, 1H), 7.35 – 7.28 (m, 4H), 7.18 (d,  $J = 9.0$  Hz, 2H), 6.89 (d,  $J = 8.2$  Hz, 1H), 5.25 (s, 2H); LC-MS (ESI+): m/z 351.08.

**3-[4-[(4-Fluorophenoxy)methyl]-1*H*-1,2,3-triazol-1-yl]phenol (4k):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (500 MHz, CD<sub>3</sub>OD): δ 8.30 (s, 1H), 7.41 – 7.35 (m, 3H), 7.06 – 7.01 (m, 4H), 6.95 (s, 1H), 5.25 (s, 2H); LC-MS (ESI+): m/z 285.08.

**2-[4-[(4-Trifluoromethoxyphenoxy)methyl]-1*H*-1,2,3-triazol-1-yl]phenol (4l):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.35$ ;  $^1\text{H}$  NMR (200 MHz, Acetone-*d*<sub>6</sub>) δ 8.63 (s, 1H), 7.89 (t,  $J = 8.3$  Hz, 2H), 7.18 (t,  $J = 7.8$  Hz, 3H), 7.09 (d,  $J = 8.0$  Hz, 1H), 7.03 (d,  $J = 9.0$  Hz, 2H); LC-MS (ESI+): m/z 351.08.

**2-[4-(4-Fluorophenoxy)methyl]-1*H*-1,2,3-triazol-1-yl}phenol (**4m**):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (200 MHz, Acetone- $d_6$ )  $\delta$  8.58 (s, 1H), 7.75 (d,  $J = 7.9$  Hz, 2H), 7.33 (t,  $J = 7.6$  Hz, 1H), 7.20 – 7.07 (m, 5H), 5.27 (s, 2H); LC-MS (ESI+): m/z 285.093.

**General procedure for the preparation triazole intermediate compounds **5a-f**:**

Reaction of azido phenol **12** (10 mmol) and substitutedphenylacetylenes **13** (12mmol) under the same procedure as mentioned for the preparation of compounds **4 a-m**, followed by purification on silica gel column chromatography using a gradient mixture of hexane-ethyl acetate to obtain the pure triazole intermediate compounds **5a-f** in 85-90% yields.

**4-[4-(4-Fluorophenyl)-1*H*-1,2,3-triazol-1-yl]phenol (**5a**):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.20$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ ):  $\delta$  8.81 (s, 1H), 8.03 (dd,  $J = 6.1, 2.7$  Hz, 2H), 7.75 (d,  $J = 9.1$  Hz, 2H), 7.24 (t,  $J = 8.9$  Hz, 2H), 7.05 (d,  $J = 9.1$  Hz, 2H); LC-MS (ESI+): m/z 255.08.

**4-[4-(4-Methoxyphenyl)-1*H*-1,2,3-triazol-1-yl]phenol (**5b**):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.35$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ ):  $\delta$  8.70 (s, 1H), 7.90 (d,  $J = 8.9$  Hz, 2H), 7.75 (d,  $J = 8.9$  Hz, 2H), 7.04 (dd,  $J = 8.9, 5.9$  Hz, 4H), 3.85 (s, 3H); LC-MS (ESI+): m/z 267.10.

**4-[4-(4-Trifluoromethylphenyl)-1*H*-1,2,3-triazol-1-yl]phenol (**5c**):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (200 MHz, Acetone- $d_6$ )  $\delta$  9.02 (s, 1H), 8.23 (d,  $J = 8.05$ Hz, 2H), 7.85 – 7.76 (m, 4H), 7.07 (d,  $J = 8.9$  Hz, 2H); LC-MS (ESI+): m/z 305.08.

**4-[4-(3-Trifluoromethylphenyl)-1*H*-1,2,3-triazol-1-yl]phenol (**5d**):** TLC (EtOAc:hexane 2:8):  $R_f = 0.22$ ;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  8.80 (s, 1H), 8.13 (s, 1H), 8.06 (d,  $J = 2.3$  Hz, 1H), 7.64 – 7.49 (m, 4H), 6.87 (d,  $J = 8.7$  Hz, 2H); LC-MS (ESI+): m/z 305.07.

**4-[4-(2-Trifluoromethylphenyl)-1*H*-1,2,3-triazol-1-yl]phenol (**5e**):** TLC (EtOAc:Hexane 2:8):  $R_f = 0.20$ ;  $^1\text{H}$  NMR (200 MHz, Acetone- $d_6$ ):  $\delta$  8.24 (s, 1H), 8.07 (d,  $J = 7.6$  Hz, 1H), 7.81 (d,  $J = 7.6$  Hz, 1H), 7.70 (d,  $J = 9.0$  Hz, 2H), 7.69 – 7.65 (m, 1H), 7.50 (t,  $J = 8.2$  Hz, 1H), 7.02 (d,  $J = 9.0$  Hz, 2H); LC-MS (ESI+): m/z 305.08.

**4-[4-(4-Trifluoromethoxyphenyl)-1*H*-1,2,3-triazol-1-yl]phenol (5f):** TLC (EtOAc: Hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (200 MHz, Acetone- $d_6$ )  $\delta$  8.95 (s, 1H), 8.09 (d,  $J = 8.3$  Hz, 2H), 7.80 (d,  $J = 8.8$  Hz, 2H), 7.46 (d,  $J = 8.34$  Hz, 2H), 7.06 (d,  $J = 8.8$  Hz, 2H); LC-MS (ESI+): m/z 321.09.

**4-Hydroxybenzaldehyde oxime 16:**

To a suspension of 4-hydroxy benzaldehyde **15** (1.2 g, 10 mmol) in a 1:1:2 mixture of H<sub>2</sub>O/EtOH/ ice (10 ml) was added hydroxylamine hydrochloride (0.695 g, 10 mmol), followed by NaOH solution (as a 50% solution in water) (1.0 g, 25 mmol) drop wise, while keeping the temperature below 30 °C. After being stirred at room temperature for 2 h, the solution was extracted with diethyl ether. The aqueous phase was acidified to  $P^H = 6$  by adding 6N HCl while keeping the temperature below 30 °C and extracted with diethyl ether. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated to give the oxime product **16** in 85% yield as yellow solid, which was used directly to the next reaction without purification.

**(Z)-N,4-dihydroxybenzimidoyl chloride 17:**

To a solution of oxime **16** (1.37 g, 10 mmol) in DMF (10 ml) was added *N*-chlorosuccinimide (0.24 g, 1.8 mmol) in one portion. The beginning of the reaction can be detected by a slight increase of the reaction temperature. The remaining NCS (1.09 g, 8.2 mmol) was added in small portions while keeping the temperature below 35 °C. The mixture was stirred at room temperature for 3 h, poured into water, and extracted with diethyl ether. The organic phase was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed to give the imidoyl chloride **17** in 90% yields. The crude product was used in the next reaction directly.

**General procedure for the preparation of isoxazolyl intermediate compounds 6a-l:**

*N*-4-dihydroxybenzimidoyl chloride **17** (0.17 g, 1.0 mmol) and substituted phenoxy methyl acetylenes **14** (1.2 mmol) were dissolved in 6 ml of a 1:1 <sup>1</sup>BuOH/H<sub>2</sub>O mixture. While the mixture was being stirred, sodium ascorbate (19.8 mg, 0.1mmol) was added, followed by copper (II) sulfate pentahydrate (2.7 mg, 0.05mmol). The reaction mixture was then treated with KHCO<sub>3</sub> (433 mg, 4.33 mmol,) and left stirring for 12 h at ambient temperature, after which time it was diluted with water and extract with ethyl acetate twice. Combined the organic layer wash with brine solution and dried over anhydrous NaSO<sub>4</sub> and filtered. The filtrate was concentrated under reduced pressure, the residue was purified by silica gel column chromatography using a gradient mixture of hexane-ethyl acetate to obtain the pure compounds **6a-l** as white solids in 80-85% yields.

**4-{5-[*p*-TolylOxy)methyl]isoxazol-3-yl}phenol (**6a**):** TLC (EtOAc:hexane 2:8): R<sub>f</sub> = 0.30; <sup>1</sup>H NMR (400 MHz, Acetone-d<sub>6</sub>) δ 7.75 (d, *J* = 8.8 Hz, 2H), 7.12 (d, *J* = 8.2 Hz, 2H), 6.97 – 6.94 (m, 4H), 6.88 (s, 1H), 5.25 (s, 2H), 2.26 (s, 3H); LC-MS (ESI+): m/z 281.11.

**4-{5-[*(4-iso-Propylphenoxy)methyl]isoxazol-3-yl}phenol (**6b**):*** TLC (EtOAc:hexane 2:8): R<sub>f</sub> = 0.35; <sup>1</sup>H NMR (400 MHz, Acetone-d<sub>6</sub>) δ 7.75 (d, *J* = 8.7 Hz, 2H), 7.20 (d, *J* = 8.7 Hz, 2H), 7.00 – 6.94 (m, 4H), 6.90 (s, 1H), 5.26 (s, 2H), 2.90 – 2.78 (m, 1H), 1.21 (d, *J* = 6.9 Hz, 6H); LC-MS (ESI+): m/z 309.14.

**4-{5-[*(4-Trifluoromethylphenoxy)methyl]isoxazol-3-yl}phenol (**6c**):*** TLC (EtOAc:hexane 2:8): R<sub>f</sub> = 0.35; <sup>1</sup>H NMR (400 MHz, Acetone-d<sub>6</sub>) δ 7.88 – 7.82 (m, 4H), 7.12 (d, *J* = 8.4 Hz, 2H), 6.98 – 6.95 (m, 3H), 5.4 (s, 2H); LC-MS (ESI+): m/z 335.07.

**4-{5-[*(4-Methoxyphenoxy)methyl]isoxazol-3-yl}phenol (**6d**):*** TLC (EtOAc:hexane 2:8): R<sub>f</sub> = 0.30; <sup>1</sup>H NMR (400 MHz, Acetone-d<sub>6</sub>) δ 7.75 (d, *J* = 8.7 Hz, 2H), 7.01 (d, *J* = 9.1 Hz, 2H), 6.95 (d, *J* = 8.7 Hz, 2H), 6.09 – 6.88 (m, 3H), 5.23 (s, 2H), 3.75 (s, 3H); LC-MS (ESI+): m/z 297.10.

**4-{5-[*(4-Trifluoromethoxyphenoxy)methyl]isoxazol-3-yl}phenol (**6e**):***

TLC (EtOAc:hexane 2:8):  $R_f = 0.35$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.76 (d,  $J = 8.7$  Hz, 2H), 7.31 (d,  $J = 8.6$  Hz, 2H), 7.19 (d,  $J = 9.2$  Hz, 2H), 6.97 - 6.95 (m, 3H), 5.35 (s, 2H); LC-MS (ESI+): m/z 351.07.

**4-{5-[(4-Fluorophenoxy)methyl]isoxazol-3-yl}phenol (6f):** TLC (EtOAc:hexane 2:8):  $R_f = 0.25$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.78 - 7.75 (m, 2H), 7.09 - 6.98 (m, 7H), 5.4 (s, 2H); LC-MS (ESI+): m/z 285.08.

**4-{5-[(4-Bromophenoxy)methyl]isoxazol-3-yl}phenol (6g):** TLC (EtOAc:hexane 2:8):  $R_f = 0.25$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.75 (d,  $J = 8.7$  Hz, 2H), 7.48 (d,  $J = 9.0$  Hz, 2H), 7.06 (d,  $J = 9.0$  Hz, 2H), 6.99 - 6.91 (m, 3H), 5.32 (s, 2H); LC-MS (ESI+): m/z 345.00.

**4-{5-[(3-Fluorophenoxy)methyl]isoxazol-3-yl}phenol (6h):** TLC (EtOAc:hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.76 (d,  $J = 8.7$  Hz, 2H), 7.36 (m, 1H), 6.99 - 6.87 (m, 5H), 6.81 - 6.74 (m, 1H), 5.35 (s, 2H); LC-MS (ESI+): m/z 285.08.

**4-{5-[(2-Fluorophenoxy)methyl]isoxazol-3-yl}phenol (6i):** TLC (EtOAc:hexane 2:8):  $R_f = 0.35$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.75 (d,  $J = 8.7$  Hz, 2H), 7.33 - 7.29 (m, 1H), 7.21 - 7.12 (m, 2H), 7.05 - 6.99 (m, 1H), 6.98 - 6.92 (m, 3H), 5.38 (s, 2H); LC-MS (ESI+): m/z 285.07.

**4-{5-[(o-Tolyloxy)methyl]isoxazol-3-yl}phenol (6j):** TLC (EtOAc:hexane 2:8):  $R_f = 0.25$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.76 (d,  $J = 8.7$  Hz, 2H), 7.17 (m, 2H), 7.09 (d,  $J = 8.2$  Hz, 1H), 6.95 (d,  $J = 8.7$  Hz, 2H), 6.93 - 6.87 (m, 2H), 5.31 (s, 1H), 2.23 (s, 3H); LC-MS (ESI+): m/z 281.10.

**4-{5-[(3-Chlorophenoxy)methyl]isoxazol-3-yl}phenol (6k):** TLC (EtOAc:hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  7.57 (d,  $J = 8.8$  Hz, 2H), 7.18 (t,  $J = 8.2$  Hz, 1H), 6.99 (t,  $J = 2.2$  Hz, 1H), 6.93 - 6.86 (m, 2H), 6.77 (d,  $J = 8.8$  Hz, 2H), 6.73 (s, 1H), 5.14 (s, 2H); LC-MS (ESI+): m/z 301.05.

**4-[5-[(4-*iso*-Propyl-3-methylphenoxy)methyl]isoxazol-3-yl]phenol (6l): TLC**

(EtOAc:hexane 2:8):  $R_f = 0.37$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.75 (d,  $J = 8.8$  Hz, 2H), 7.18 (d,  $J = 8.2$  Hz, 1H), 6.95 (d,  $J = 8.8$  Hz, 2H), 6.91 (d,  $J = 8.2$  Hz, 1H), 6.89 (s, 1H), 6.85 (s, 1H), 5.24 (s, 2H), 3.20 – 3.00 (m, 1H), 2.31 (s, 3H), 1.18 (d,  $J = 6.9$  Hz, 6H); LC-MS (ESI+): m/z 323.15.

**General procedure for the preparation of isoxazolyl intermediate compounds 7a-j:**

Reaction of N-4-dihydroxybenzimidoyl chloride **17**(0.17 g, 1.0 mmol) and substitutedphenylacetylene **18** (12mmol) under the same procedure as mentioned for the preparation of compounds **6 a-l**, followed by purification on silica gel column chromatography using a gradient mixture of hexane-ethyl acetate to obtain the pure isoxazole intermediate compounds **7a-j** as a white solids in 85-90% yields.

**4-(5-Phenylisoxazol-3-yl)phenol (7a):** TLC (EtOAc:hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.92 – 7.98 (m, 2H), 7.78 (d,  $J = 8.6$  Hz, 2H), 7.50 – 7.55 (m, 3H), 7.15 (s, 1H), 6.92 (d,  $J = 8.6$  Hz, 2H); LC-MS (ESI+): m/z 237.08.

**4-[5-(*p*-Tolyl)isoxazol-3-yl]phenol (7b):** TLC (EtOAc:hexane 2:8):  $R_f = 0.32$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.85 – 7.81 (m, 4H), 7.39 (d,  $J = 8.6$  Hz, 2H), 7.18 (s, 1H), 6.98 (d,  $J = 8.6$  Hz, 2H), 2.38 (s, 3H); LC-MS (ESI+): m/z 251.09.

**4-[5-(4-Fluorophenyl)isoxazol-3-yl]phenol (7c):** TLC (EtOAc:hexane 2:8):  $R_f = 0.35$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.97-8.05 (m, 2H), 7.78 (d,  $J = 8.5$  Hz, 2H), 7.25-7.31 (m, 3H), 6.92 (d,  $J = 8.5$  Hz, 2H); LC-MS (ESI+): m/z 255.06.

**4-[5-(4-Methoxyphenyl)isoxazol-3-yl]phenol (7d):** TLC (EtOAc:hexane 2:8):  $R_f = 0.20$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.74-7.81 (m, 4H), 6.95 – 7.11 (m, 5H), 3.92 (s, 3H); LC-MS (ESI+): m/z 267.08.

**4-[5-(4-Trifluoromethylphenyl)isoxazol-3-yl]phenol (7e):** TLC (EtOAc:hexane 2:8):  $R_f = 0.35$ ;  $^1\text{H}$  NMR (200 MHz, CD<sub>3</sub>OD)  $\delta$  8.11 (d,  $J = 7.6$  Hz, 2H), 7.88–7.92 (m, 4H), 7.52 (s, 1H), 7.02 (d,  $J = 8.5$  Hz, 2H); LC-MS (ESI+): m/z 305.06.

**4-[5-(4-Trifluoromethoxyphenyl)isoxazol-3-yl]phenol (7f):** TLC (EtOAc:hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  8.07 (d,  $J = 7.3$  Hz, 2H), 7.83 (d,  $J = 8.3$  Hz, 2H), 7.56 (d,  $J = 7.3$  Hz, 2H), 7.37 (s, 1H), 6.99 (d,  $J = 8.3$  Hz, 2H); LC-MS (ESI+): m/z 321.06.

**4-[5-(3-Trifluoromethylphenyl)isoxazol-3-yl]phenol (7g):** TLC (EtOAc:hexane 2:8):  $R_f = 0.35$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  8.22 (m, 1H), 7.89 – 7.79 (m, 5H), 7.51 (s, 1H), 6.99 (d,  $J = 8.7$  Hz, 2H); LC-MS (ESI+): m/z 305.08.


**4-[5-(2-Trifluoromethylphenyl)isoxazol-3-yl]phenol (7h):** TLC (EtOAc:hexane 2:8):  $R_f = 0.30$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  7.98 (d,  $J = 7.8$  Hz, 1H), 7.93 – 7.78 (m, 5H), 7.11 (s, 1H), 6.99 (d,  $J = 8.5$  Hz, 2H); LC-MS (ESI+): m/z 305.08.

**4-[5-(2-Fluorophenyl)isoxazol-3-yl]phenol (7i):** TLC (EtOAc:hexane 2:8):  $R_f = 0.25$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  8.03 – 8.01 (m, 1H), 7.84 (d,  $J = 8.5$  Hz, 2H), 7.62 – 7.56 (m, 1H), 7.44 – 7.35 (m, 2H), 7.20 – 7.18 (m, 1H), 6.99 (d,  $J = 8.5$  Hz, 2H); LC-MS (ESI+): m/z 255.08.


**4-[5-(2,4-Difluorophenyl)isoxazol-3-yl]phenol (7j):** TLC (EtOAc:hexane 2:8):  $R_f = 0.40$ ;  $^1\text{H}$  NMR (400 MHz, Acetone- $d_6$ )  $\delta$  8.07 – 8.03 (m, 1H), 7.80 (d,  $J = 8.8$  Hz, 2H), 7.33 – 7.26 (m, 2H), 7.17 (s, 1H), 6.98 (d,  $J = 8.8$  Hz, 2H); LC-MS (ESI+): m/z 273.07.

**<sup>1</sup>H NMR, <sup>13</sup>C NMR, DEPT and HRMS of triazolyl and isoxazolyl based NHIO compounds 1 & 2:**


<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) of compound **1a** (IIIM/MCD-023):




HRMS (ESI-TOF) of compound **1a (IIIM/MCD-023)**:




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) of compound **1b** (IIIM/MCD-024):




HRMS (ESI-TOF) of compound **1b** (IIIM/MCD-024):




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **1c** (**IIIM/MCD-026**):




$^{13}\text{C}$  NMR (101 MHz, Acetone- $d_6$ ) of compound **1c** (IIIM/MCD-026):




DEPT (101 MHz, Acetone- $d_6$ ) of compound **1c** (IIIM/MCD-026):




HRMS (ESI-TOF) of compound **1c (IIIM/MCD-026)**:




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **1d** (IIIM/MCD-027):




$^{13}\text{C}$  NMR (101 MHz, Acetone- $d_6$ ) of compound **1d** (**IIIM/MCD-027**):




DEPT (101 MHz, Acetone- $d_6$ ) of compound **1d** (**IIIM/MCD-027**):




HRMS (ESI-TOF) of compound **1d** (IIIM/MCD-027):




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) of compound **1e** (**IIIM/MCD-028**):




$^{13}\text{C}$  NMR (101 MHz, Acetone- $d_6$ ) of compound **1e** (IIM/MCD-028):




DEPT (101 MHz, Acetone- $d_6$ ) of compound **1e** (IIM/MCD-028):




HRMS (ESI-TOF) of compound **1e** (IIM/MCD-028):




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **1f** (IIIM/MCD-025):



<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>) of compound **1f** (**IIM/MCD-025**):



<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>) of compound **1f** (**IIM/MCD-025**):



HRMS (ESI-TOF) of compound **1f (IIIM/MCD-025)**:


**Qualitative Compound Report**

Data File	25.d	Sample Name	25
Sample Type	Sample	Position	Vial 9
Instrument Name	Instrument 1	User Name	vishal
Acq Method	vishal_12-01-13.m	Acquired Time	18-04-2013 PM 1:38:00
IRM Calibration Status	Success	DA Method	daily_report.m
Comment			

Sample Group  
Acquisition SW  
Version

Info.

6200 series TOF/6500 series  
Q-TOF B.05.01 (B5125)




**Compound Table**

Compound Label	RT	Mass	Formula	MFG Formula	MFG Diff (ppm)	DB Formula
Cpd 38: C23 H19 F3 N6 O5	0.189	516.1383	C23 H19 F3 N6 O5	C23 H19 F3 N6 O5	-2.68	C23 H19 F3 N6 O5

Compound Label	m/z	RT	Algorithm	Mass
Cpd 38: C23 H19 F3 N6 O5	539.1277	0.189	Find by Molecular Feature	516.1383

MFE MS Spectrum



**MS Spectrum Peak List**


m/z	z	Abund	Formula	Ion
517.1444	1	103022.23	C23 H20 F3 N6 O5	(M+H)+
518.1473	1	26483.53	C23 H20 F3 N6 O5	(M+H)+
519.1496	1	3956.01	C23 H20 F3 N6 O5	(M+H)+
520.1521	1	929.27	C23 H20 F3 N6 O5	(M+H)+
539.1277	1	466341.94	C23 H19 F3 N6 Na O5	(M+Na)+
540.1298	1	124198.54	C23 H19 F3 N6 Na O5	(M+Na)+
541.1315	1	18573.32	C23 H19 F3 N6 Na O5	(M+Na)+
542.1345	1	2460.49	C23 H19 F3 N6 Na O5	(M+Na)+
543.1446	1	310.04	C23 H19 F3 N6 Na O5	(M+Na)+

**Predicted Isotope Match Table**


Isotope	m/z	Calc m/z	Diff (ppm)	Abund %	Calc Abund %	Abund Sum %	Calc Abund Sum %
1	517.1444	517.1442	-0.44	100	100	76.66	75.33
2	518.1473	518.1471	-0.56	25.71	27.49	19.71	20.71
3	519.1496	519.1496	-0.04	3.84	4.67	2.94	3.52
4	520.1521	520.1521	0.01	0.9	0.59	0.69	0.45

--- End Of Report ---


<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **1g** (**IIIM/MCD-019**):




$^{13}\text{C}$  NMR (101 MHz, Acetone- $d_6$ ) of compound **1g (IIIM/MCD-019)**:




DEPT (101 MHz, Acetone- $d_6$ ) of compound **1g (IIIM/MCD-019)**:




HRMS (ESI-TOF) of compound **1g (IIIM/MCD-019)**:




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) of compound **1h** (IIIM/MCD-031):




<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **1h** (IIIM/MCD-031):




DEPT (126 MHz, Acetone-*d*<sub>6</sub>) of compound **1h** (IIIM/MCD-031):




HRMS (ESI-TOF) of compound **1h (IIIM/MCD-031)**:




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **1i** (IIM/MCD-030):




<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **1i** (IIIM/MCD-030):




DEPT (126 MHz, Acetone-*d*<sub>6</sub>) of compound **1i** (IIIM/MCD-030):




HRMS (ESI-TOF) of compound **1i (IIIM/MCD-030)**:



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **1j** (IIIIM/MCD-047):




<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **1j** (IIIIM/MCD-047):




DEPT (126 MHz, Acetone-*d*<sub>6</sub>) of compound **1j** (IIM/MCD-047):


pp singh  
47




HRMS (ESI-TOF) of compound **1j** (IIM/MCD-047):




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **1k** (IIIM/MCD-048):




<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **1k** (IIIM/MCD-048):




DEPT (126 MHz, Acetone- $d_6$ ) of compound **1k (IIIM/MCD-048)**:




HRMS (ESI-TOF) of compound **1k (IIIM/MCD-048)**:




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **1l** (IIIM/MCD-052):




<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) of compound **1l** (IIIM/MCD-052):




DEPT (101 MHz, CDCl<sub>3</sub>) of compound **1l** (IIM/MCD-052):




HRMS (ESI-TOF) of compound **1l** (IIM/MCD-052):



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **1m** (IIIM/MCD-063):




HRMS (ESI-TOF) of compound **1m** (IIIM/MCD-063):




--- End Of Report ---


<sup>1</sup>H NMR (500 MHz, Acetone-*d*<sub>6</sub>) of compound **1n** (IIM/MCD-065):




HRMS (ESI-TOF) of compound **1n (IIIM/MCD-065)**:




<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **1o** (IIIIM/MCD-066):




HRMS (ESI-TOF) of compound **1o** (IIIM/MCD-066):




<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **1p** (III M/MCD-067):




HRMS (ESI-TOF) of compound **1p (IIIM/MCD-067)**:




<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **1q** (IIIM/MCD-178):




<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>) of compound **1q** (IIIM/MCD-178):




DEPT (101 MHz, Acetone- $d_6$ ) of compound **1q** (IIIM/MCD-178):




LC-MS (ESI-TOF) of compound **19** (IIIM/MCD-178):




<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **1r** (IIIIM/MCD-051):




<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>) of compound **1r** (IIIIM/MCD-051):




DEPT (101 MHz, Acetone-*d*<sub>6</sub>) of compound **1r (IIIM/MCD-051)**:




HRMS (ESI-TOF) of compound **1r (IIIM/MCD-051)**:




<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **1s** (IIIM/MCD-068):




<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **1s** (IIIM/MCD-068):




DEPT (126 MHz, Acetone-*d*<sub>6</sub>) of compound **1s** (IIM/MCD-068):




HRMS (ESI-TOF) of compound **1s (IIIM/MCD-068)**:




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2a** (IIIM/MCD-118):




<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>) of compound **2a** (IIIM/MCD-118):




DEPT (101 MHz, Acetone-*d*<sub>6</sub>) of compound **2a** (IIIM/MCD-118):




HRMS (ESI-TOF) of compound **2a (IIIM/MCD-118)**:




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2b** (IIIM/MCD-116):



$^{13}\text{C}$  NMR (126 MHz, Acetone- $d_6$ ) of compound **2b (IIM/MCD-116)**:




DEPT (126 MHz, Acetone- $d_6$ ) of compound **2b (IIM/MCD-116)**:



HRMS (ESI-TOF) of compound **2b** (IIIM/MCD-116):


## Qualitative Compound Report

Data File	116.d	Sample Name	116
Sample Type	Sample	Position	Vial 33
Instrument Name	Instrument 1	User Name	vishal
Acq Method	vishal_12-01-13.m	Acquired Time	22-04-2013 PM 12:25:04
IRM Calibration Status	Success	DA Method	daily_report.m
Comment			



Compound Table					MFG DIFF (ppm)	DB Formula
Compound Label	RT	Mass	Formula	MFG Formula		
Cpd 29: C26 H26 N4 O6	0.191	490.1865	C26 H26 N4 O6	C26 H26 N4 O6	-2.55	C26 H26 N4 O6

Compound Label	<i>m/z</i>	RT	Algorithm	Mass
Cpd 29: C26 H26 N4 O6	491.194	0.191	Find by Molecular Feature	490.1865




MS Spectrum Peak List				
m/z	z	Abund	Formula	Ion
491.194	1	701826.5	C26 H27 N4 O6	(M+H)+
492.1963	1	192840.44	C26 H27 N4 O6	(M+H)+
493.1987	1	35753.47	C26 H27 N4 O6	(M+H)+
494.2015	1	5000.45	C26 H27 N4 O6	(M+H)+
508.2191	1	10525.7	C26 H30 N5 O6	(M+NH4)+
509.2219	1	3174.05	C26 H30 N5 O6	(M+N+H)+
513.1752	1	214633.56	C26 H26 N4 Na O6	(M+Na)+
514.1778	1	63898.27	C26 H26 N4 Na O6	(M+Na)+
515.1801	1	12696.37	C26 H26 N4 Na O6	(M+Na)+
516.1824	1	2273.56	C26 H26 N4 Na O6	(M+Na)+


Predicted Isotope Match Table						
Isotope	m/z	Calc m/z	Diff (ppm)	Abund %	Calc Abund %	Abund Sum %
1	491.194	491.1925	-2.96	100	100	74.96
2	492.1963	492.1956	-1.35	27.48	30.12	20.6
3	493.1987	493.1982	-1	5.09	5.61	3.82
4	494.2015	494.2008	-1.27	0.71	0.78	0.53
5	495.2077	495.2034	-8.72	0.13	0.09	0.1

--- End Of Report ---


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2c** (**IIIM/MCD-115**):




<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2c** (IIIM/MCD-115):




DEPT (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2c** (IIIM/MCD-115):




HRMS (ESI-TOF) of compound **2c (IIIM/MCD-115)**:




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2d** (IIIM/MCD-128):




<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>) of compound **2d** (IIIM/MCD-128):




DEPT (101 MHz, Acetone-*d*<sub>6</sub>) of compound **2d** (IIIM/MCD-128):




HRMS (ESI-TOF) of compound **2d (IIIM/MCD-128)**:




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2e** (IIIM/MCD-069):




$^{13}\text{C}$  NMR (101 MHz, Acetone- $d_6$ ) of compound **2e** (IIIM/MCD-069):




DEPT (101 MHz, Acetone- $d_6$ ) of compound **2e** (IIIM/MCD-069):




HRMS (ESI-TOF) of compound **2e** (IIIM/MCD-069):




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2f** (IIIM/MCD-114):




$^{13}\text{C}$  NMR (101 MHz, Acetone- $d_6$ ) of compound **2f (IIM/MCD-114)**:




DEPT (101 MHz, Acetone- $d_6$ ) of compound **2f (IIM/MCD-114)**:




HRMS (ESI-TOF) of compound **2f (IIM/MCD-114)**:




<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **2g** (**IIIM/MCD-127**):




$^{13}\text{C}$  NMR (126 MHz, Acetone- $d_6$ ) of compound **2g (IIIM/MCD-127)**:



DEPT (126 MHz, Acetone- $d_6$ ) of compound **2g (IIIM/MCD-127)**:



HRMS (ESI-TOF) of compound **2g (IIIM/MCD-127)**:




Agilent Technologies


Page 1 of 1

Printed at: 3:13 PM on:04-03-2013


<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **2h** (IIIM/MCD-175):




<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>) of compound **2h** (IIIM/MCD-175):




DEPT (101 MHz, Acetone-*d*<sub>6</sub>) of compound **2h** (IIIM/MCD-175):




LC-MS (ESI-TOF) of compound **2h** (IIIM/MCD-175):




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2i** (IIIM/MCD-117):




$^{13}\text{C}$  NMR (101 MHz, Acetone- $d_6$ ) of compound **2i** (IIIM/MCD-117):




DEPT (101 MHz, Acetone- $d_6$ ) of compound **2i** (IIIM/MCD-117):




HRMS (ESI-TOF) of compound **2i (IIM/MCD-117)**:




<sup>1</sup>H NMR (500 MHz, Acetone-*d*<sub>6</sub>) of compound **2j** (IIIM/MCD-177):




<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2j** (IIIM/MCD-177):




DEPT (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2j** (IIIIM/MCD-177):




LC-MS (ESI-TOF) of compound **2j** (IIIIM/MCD-177):




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2k** (**IIIM/MCD-138**):



<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2k** (IIM/MCD-138):



DEPT (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2k** (IIM/MCD-138):




HRMS (ESI-TOF) of compound **2k (IIIM/MCD-138)**:

### Qualitative Compound Report

Data File	138.d	Sample Name	138
Sample Type	Sample	Position	Vial 31
Instrument Name	Instrument 1	User Name	
Acq Method	vishal_12-01-13.m	Acquired Time	05-03-2013 PM 3:38:02
IRM Calibration Status	Success	DA Method	SamplePurity-Default.m
Comment			

Sample Group Info.  
 Acquisition SW 6200 series TOF/6500 series  
 Version Q-TOF B.05.01 (B5125)




Compound Table

Compound Label	RT	Mass	Formula	MFG Formula	MFG Diff (ppm)	DB Formula
Cpd 6: C23 H19 Cl N4 O6	0.194	482.1	C23 H19 Cl N4 O6	C23 H19 Cl N4 O6	-1.51	C23 H19 Cl N4 O6

Compound Label	m/z	RT	Algorithm	Mass
Cpd 6: C23 H19 Cl N4 O6	483.1072	0.194	Find by Molecular Feature	482.1

MFE MS Spectrum



MS Spectrum Peak List


m/z	z	Abund	Formula	Ion
483.1072	1	66364.26	C23 H20 Cl N4 O6	(M+H)+
484.1105	1	16561.47	C23 H20 Cl N4 O6	(M+H)+
485.1055	1	22645.74	C23 H20 Cl N4 O6	(M+H)+
505.089	1	55288.79	C23 H19 Cl N4 Na O6	(M+Na)+
506.092	1	14155.97	C23 H19 Cl N4 Na O6	(M+Na)+
507.0877	1	20617.74	C23 H19 Cl N4 Na O6	(M+Na)+
987.1911	1	36689.49		(2M+Na)+
988.1924	1	18270.32		(2M+Na)+
989.1886	1	28889.01		(2M+Na)+
990.1906	1	13964		(2M+Na)+

Predicted Isotope Match Table


Isotope	m/z	Calc m/z	Diff (ppm)	Abund %	Calc Abund %	Abund Sum %	Calc Abund Sum %
1	483.1072	483.1066	-1.32	100	100	58.94	57.4
2	484.1105	484.1096	-1.73	24.96	26.8	14.71	15.38
3	485.1055	485.1047	-1.67	34.12	36.68	20.11	21.05
4	486.1083	486.1072	-2.26	8.6	9.19	5.07	5.27
5	487.1102	487.1096	-1.23	1.98	1.56	1.17	0.9

--- End Of Report ---


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2l** (IIIM/MCD-139):



<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>) of compound **2l** (IIIM/MCD-139):



DEPT (101 MHz, Acetone-*d*<sub>6</sub>) of compound **2l** (IIIM/MCD-139):




HRMS (ESI-TOF) of compound **2l** (IIIM/MCD-139):

### Qualitative Compound Report

Data File	139.d	Sample Name	139
Sample Type	Sample	Position	Vial 33
Instrument Name	Instrument 1	User Name	
Acq Method	vishal_12-01-13.m	Acquired Time	05-03-2013 PM 3:54:42
IRM Calibration Status	Success	DA Method	SamplePurity-Default.m
Comment			

Sample Group  
6200 series TOF/6500 series  
Acquisition SW  
Q-TOF B.05.01 (B5125)  
Version

Info.




Compound Table

Compound Label	RT	Mass	Formula	MFG Formula	MFG Diff (ppm)	DB Formula
Cpd 5: C27 H28 N4 O6	0.189	504.2029	C27 H28 N4 O6	C27 H28 N4 O6	-3.93	C27 H28 N4 O6

Compound Label	m/z	RT	Algorithm	Mass
Cpd 5: C27 H28 N4 O6	505.2101	0.189	Find by Molecular Feature	504.2029

MFE MS Spectrum



MS Spectrum Peak List


m/z	z	Abund	Formula	Ion
505.2101	1	66789.78	C27 H29 N4 O6	(M+H)+
506.2136	1	19373.52	C27 H29 N4 O6	(M+H)+
507.2157	1	4010.87	C27 H29 N4 O6	(M+H)+
508.216	1	553.01	C27 H29 N4 O6	(M+H)+
522.236	1	4510.39	C27 H32 N5 O6	(M+NH4)+
523.2393	1	1484.27	C27 H32 N5 O6	(M+NH4)+
527.192	1	58944.45	C27 H28 N4 Na O6	(M+Na)+
528.1949	1	16879.33	C27 H28 N4 Na O6	(M+Na)+
529.1976	1	4230.34	C27 H28 N4 Na O6	(M+Na)+
530.1944	1	773.05	C27 H28 N4 Na O6	(M+Na)+

Predicted Isotope Match Table


Isotope	m/z	Calc m/z	Diff (ppm)	Abund %	Calc Abund %	Abund Sum %	Calc Abund Sum %
1	505.2101	505.2082	-3.79	100	100	73.62	72.46
2	506.2136	506.2113	-4.6	29.01	31.23	21.35	22.62
3	507.2157	507.2139	-3.52	6.01	5.95	4.42	4.31
4	508.216	508.2165	1.14	0.83	0.84	0.61	0.61

--- End Of Report ---


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2m** (IIIM/MCD-050):




<sup>13</sup>C NMR (126 MHz, pyridine-*d*<sub>5</sub>) of compound **2m** (IIIM/MCD-050):




DEPT (126 MHz, pyridine-*d*<sub>5</sub>) of compound **2m** (IIIM/MCD-050):




HRMS (ESI-TOF) of compound **2m** (IIIM/MCD-050):



<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **2n** (IIM/MCD-072):




HRMS (ESI-TOF) of compound **2n** (IIIM/MCD-072):




--- End Of Report ---


<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **2o** (IIIM/MCD-119):




HRMS (ESI-TOF) of compound **2o (IIIM/MCD-119)**:




<sup>1</sup>H NMR (500 MHz, Acetone-*d*<sub>6</sub>) of compound **2p** (IIIM/MCD-071):




HRMS (ESI-TOF) of compound **2p (IIIM/MCD-071)**:



<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **2q** (IIM/MCD-073):




HRMS (ESI-TOF) of compound **2q** (IIIM/MCD-073):




--- End Of Report ---


<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **2r** (IIIM/MCD-074):




<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2r** (IIIM/MCD-074):




DEPT (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2r** (IIIM/MCD-074):




HRMS (ESI-TOF) of compound **2r** (IIIM/MCD-074):




<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **2s** (IIIM/MCD-125):



<sup>13</sup>C NMR (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2s** (IIIM/MCD-125):



DEPT (126 MHz, Acetone-*d*<sub>6</sub>) of compound **2s** (IIIM/MCD-125):




HRMS (ESI-TOF) of compound **2s (IIIM/MCD-125)**:

### Qualitative Compound Report

Data File	125.d	Sample Name	125
Sample Type	Sample	Position	Vial 25
Instrument Name	Instrument 1	User Name	vishal_12-01-13.m
Acq Method	vishal_12-01-13.m	Acquired Time	04-03-2013 PM 2:39:23
IRM Calibration Status	Success	DA Method	SamplePurity-Default.m
Comment			

Sample Group  
6200 series TOF/6500 series  
Acquisition SW  
Version Q-TOF B.05.01 (B5125)

Info.




Compound Table

Compound Label	RT	Mass	Formula	MFG Formula	MFG Diff (ppm)	DB Formula
Cpd 4: C23 H17 F3 N4 O5	0.192	486.1149	C23 H17 F3 N4 O5	C23 H17 F3 N4 O5	0.41	C23 H17 F3 N4 O5

Compound Label	m/z	RT	Algorithm	Mass
Cpd 4: C23 H17 F3 N4 O5	487.1223	0.192	Find by Molecular Feature	486.1149

MFE MS Spectrum



MS Spectrum Peak List


m/z	z	Abund	Formula	Ion
487.1223	1	64273.68	C23 H18 F3 N4 O5	(M+H)+
488.1251	1	16923.33	C23 H18 F3 N4 O5	(M+H)+
489.1272	1	3450.28	C23 H18 F3 N4 O5	(M+H)+
509.104	1	44775.54	C23 H17 F3 N4 Na O5	(M+Na)+
510.1072	1	11174.5	C23 H17 F3 N4 Na O5	(M+Na)+
973.2376	1	5185.26		(2M+H)+
974.2366	1	2962.2		(2M+H)+
995.2204	1	18278.33		(2M+Na)+
996.2211	1	9595.55		(2M+Na)+
997.2244	1	3231.42		(2M+Na)+

Predicted Isotope Match Table


Isotope	m/z	Calc m/z	Diff (ppm)	Abund %	Calc Abund %	Abund Sum %	Calc Abund Sum %
1	487.1223	487.1224	0.17	100	100	75.37	75.9
2	488.1251	488.1254	0.75	26.33	26.73	19.85	20.29
3	489.1272	489.128	1.68	5.37	4.46	4.05	3.39
4	490.1261	490.1306	9.2	0.97	0.56	0.73	0.42

--- End Of Report ---


<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **2t** (IIIM/MCD-176):




<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>) of compound **2t** (IIIM/MCD-176):




DEPT (101 MHz, Acetone-d<sub>6</sub>) of compound **2t** (IIIM/MCD-176):




LC-MS (ESI-TOF) of compound **2t** (IIIM/MCD-176):




<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) of compound **2u** (IIIM/MCD-126):



HRMS (ESI-TOF) of compound **2u (IIIM/MCD-126)**:



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2v** (IIIM/MCD-070):



HRMS (ESI-TOF) of compound **2v (IIIM/MCD-070)**:

